In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against α4β1 integrin

Molecular Cancer Therapeutics

Volumn 7, Issue 2, 2008, Pages 432-437

  Peng, Li ^a   Liu, Ruiwu ^a   Andrei, Mirela ^a   Xiao, Wenwu ^a   Lam, Kit S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CANCER SURGERY; COMBINATORIAL LIBRARY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; IN VIVO STUDY; KIDNEY TUBULE; LYMPHOMA; MICROSCOPY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; BIOMIMETICS; CARBOCYANINES; FEMALE; FLUORESCENT DYES; HUMANS; INTEGRIN ALPHA4BETA1; LYMPHOMA; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; PEPTIDE LIBRARY; SUBSTRATE SPECIFICITY; TOMOGRAPHY, OPTICAL; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; WHOLE BODY IMAGING;

EID: 39749130389     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0575     Document Type: Article

References (38)

1. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-7.
2. Martin KH, Slack JK, Boerner SA, Martin CC, Parsons JT. Integrin connections map: to infinity and beyond. Science 2002;296:1652-3.
3. Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 2004;18:991-1006.
4. Shimaoka M, Takagi J, Springer TA. Conformational regulation of integrin structure and function. Annu Rev Biophys Biomol Struct 2002;31:485-516.
5. Sivolapenko GB, Skarlos D, Pectasides D, et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med 1998;25:1383-9.
6. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of α(v)β3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5.
7. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled α(v)β(3) integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-51.
8. Su ZF, He J, Rusckowski M, Hnatowich DJ. In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands. Nucl Med Biol 2003;30:141-9.
9. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin avh3 in brain tumor xenografts. Cancer Res 2004;64:8009-14.
10. Chen X. Multimodality imaging of tumor integrin αvβ3 expression. Mini Rev Med Chem 2006;6:227-34.
11. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003;2:703-16.
12. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004;90:561-5.
13. Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin αvβ3 antagonism. Anticancer Agents Med Chem 2006;6:407-28.
14. Lin KC, Castro AC. Very late antigen 4 (VLA4) antagonists as antiinflammatory agents. Curr Opin Chem Biol 1998;2:453-7.
15. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 2002;22:146-67.
16. Holzmann B, Gosslar U, Bittner M. α4 integrins and tumor metastasis. Curr Top Microbiol Immunol 1998;231:125-41.
17. Vincent AM, Cawley JC, Burthem J. Integrin function in chronic lymphocytic leukemia. Blood 1996;87:4780-8.
18. Marco RA, Diaz-Montero CM, Wygant JN, Kleinerman ES, McIntyre BW. α4 integrin increases anoikis of human osteosarcoma cells. J Cell Biochem 2003;88:1038-47.
19. de la Fuente MT, Casanova B, Garcia-Gila M, Silva A, Garcia-Pardo A. Fibronectin interaction with α4β1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999;13:266-74.
20. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 2000;38:71-81.
21. Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003;9:1158-65.
22. Olson DL, Burkly LC, Leone DR, Dolinski BM, Lobb RR. Anti-α4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol Cancer Ther 2005;4:91-9.
23. Garmy-Susini B, Jin H, Zhu Y, Sung RJ, Hwang R, Varner J. Integrin α4β1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. J Clin Invest 2005;115:1542-51.
24. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS. Combinatorial chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging. Nat Chem Biol 2006;2:381-9.
25. Jin H, Su J, Garmy-Susini B, Kleeman J, Varner J. Integrin α4β1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res 2006;66:2146-52.
26. Park SI, Manat R, Vikstrom B, Amro N, Song LW, Lam KS. The use of one-bead one-compound combinatorial library method to identify peptide ligands for α-4-β-1 integrin receptor in non-Hodgkin's lymphoma. Lett Pept Sci 2002;8:171-8.
27. O'Byrne KJ, Carney DN. Radiolabelled somatostatin analogue scintigraphy in oncology. Anticancer Drugs 1996;7:33-44.
28. Becker A, Hessenius C, Licha K, et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol 2001;19:327-31.
29. Bhargava S, Licha K, Knaute T, et al. A complete substitutional analysis of VIP for better tumor imaging properties. J Mol Recognit 2002;15:145-53.
30. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 2003;13:195-208.
31. Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol 2005;23:313-20.
32. Weissleder R, Tung CH, Mahmood U, Bogdanov A, Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999;17:375-8.
33. Ke S, Wen X, Gurfinkel M, et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 2003;63:7870-5.
34. Song A, Wang X, Zhang J, Marik J, Lebrilla CB, Lam KS. Synthesis of hydrophilic and flexible linkers for peptide derivatization in solid phase. Bioorg Med Chem Lett 2004;14:161-5.
35. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic Cancer Targeting Peptides. Biopolymers 2002;66:184-99.
36. Aina OH, Marik J, Liu R, Lau DH, Lam KS. Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries. Mol Cancer Ther 2005;4:806-13.
37. Aina OH, Marik J, Gandour-Edwards R, Lam KS. Near-infrared optical imaging of ovarian cancer xenografts with novel α3-integrin binding peptide "OA02." Mol Imaging 2005;4:439-47.
38. Lau D, Guo L, Liu R, Marik J, Lam KS. Peptide ligands targeting integrin α3β1 in non-small cell lung cancer. Lung Cancer 2006;52:291-7.